Ovid Therapeutics Inc (NASDAQ:OVID) – Research analysts at William Blair issued their Q1 2018 EPS estimates for shares of Ovid Therapeutics in a research note issued on Wednesday. William Blair analyst T. Lugo expects that the company will post earnings of ($0.48) per share for the quarter. William Blair also issued estimates for Ovid Therapeutics’ Q2 2018 earnings at ($0.54) EPS, Q3 2018 earnings at ($0.59) EPS and Q4 2018 earnings at ($0.58) EPS.

Ovid Therapeutics (NASDAQ:OVID) last issued its quarterly earnings results on Thursday, November 9th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.54) by $0.16.

Separately, Zacks Investment Research downgraded Ovid Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, August 16th. Five research analysts have rated the stock with a buy rating, The company has a consensus rating of “Buy” and a consensus price target of $19.33.

Ovid Therapeutics (NASDAQ OVID) traded down $0.79 during trading hours on Friday, reaching $11.52. The company’s stock had a trading volume of 84,046 shares, compared to its average volume of 61,426. Ovid Therapeutics has a 1 year low of $5.28 and a 1 year high of $15.93.

A number of large investors have recently added to or reduced their stakes in the stock. Jennison Associates LLC bought a new position in Ovid Therapeutics during the 2nd quarter worth $6,739,000. Alps Advisors Inc. bought a new stake in Ovid Therapeutics during the 2nd quarter worth $233,000. Sphera Funds Management LTD. bought a new stake in Ovid Therapeutics during the 2nd quarter worth $3,042,000. Ameriprise Financial Inc. acquired a new position in Ovid Therapeutics during the 2nd quarter worth about $3,761,000. Finally, Goldman Sachs Group Inc. acquired a new position in Ovid Therapeutics during the 2nd quarter worth about $923,000. 29.36% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: This news story was originally reported by American Banking News and is the sole property of of American Banking News. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of US and international trademark and copyright law. The legal version of this news story can be accessed at https://www.americanbankingnews.com/2017/12/01/ovid-therapeutics-inc-forecasted-to-post-q1-2018-earnings-of-0-48-per-share-ovid.html.

Ovid Therapeutics Company Profile

Ovid Therapeutics Inc (Ovid) is a biopharmaceutical company. The Company is engaged in developing medicines for patients and families living with rare neurological disorders. Its lead drug candidate is OV101. The Company’s second lead drug candidate is OV935. OV101 (gaboxadol) is a delta-selective GABAA receptor agonist.

Earnings History and Estimates for Ovid Therapeutics (NASDAQ:OVID)

Receive News & Ratings for Ovid Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ovid Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.